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INTRODUCTION
N-3 (omega-3) (polyunsaturated) fatty acids, mainly
eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA), feature a variety of beneficial effects for human
health, ranging from fetal development to cancer pre-
vention (1). However, cardiovascular protective effects
have been the spur for the first biomedical interest in
these compounds, and are the best documented. The
epidemiologic association between dietary consump-
tion of n-3 fatty acids and cardiovascular protection
was first suggested by Bang and Dyerberg (2, 3). The
authors identified the high consumption of fish, and
therefore, of fish oil-derived n-3 fatty acids, as the likely
explanation for the strikingly low rate of coronary heart
disease events reported in the Inuit population (2, 3).
Since their initial reports, research has proceeded in
parallel to provide further evidence for this cardiopro-
tection and to understand underlying mechanisms. De-
creased atherogenesis is currently thought to be a part
of the cardiovascular protection by n-3 fatty acids, and
is likely to occur in addition to effects on arrhythmias
and sudden cardiac death (4, 5), as recently reviewed
(6). This article summarizes the evidence for such a
claim and the mechanisms putatively involved.
EVIDENCE FOR ANTIATHEROGENIC EFFECTS OF N-3
FATTY ACIDS
Effects of n-3 fatty acid in animal models of
atherosclerosis
In animal models, the hypotriglyceridemic action of
n-3 fatty acids, which is very well documented in hu-
mans, is not consistently observed, while a reduction in
high density lipoprotein (HDL)-cholesterol has been
consistently reported (7). Putative antiatherogenic ef-
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fects of n-3 fatty acids are, therefore, not attributable to
the favorable effects on serum lipids that occur in hu-
mans (see below). N-3 fatty acids have been reported to
lessen the development of atherosclerotic lesions in
several animal models. However, results have not been
unequivocal due to differences between species cho-
sen and variations in study design. N-3 fatty acids were
usually supplemented as fish oils. Studies aimed at de-
termining their effect on atherogenesis or on lesion re-
gression have been performed in non-human primates,
pigs, rabbits and mice. The design of most of these
studies has been criticized for a variety of reasons. One
is that the supplementation with fish oils reached ex-
tremely high levels, between 10 and 40% of total energy
intake as n-3 fatty acids, in most studies, while realistic
values should be 1-2% (7). Another reason is the fre-
quent lack of an appropriate control. In some cases, fish
oils were simply substituted for saturated fats; in others,
the control oil had a different polyunsaturated/saturated
(P/S) ratio, a variable that might per se have an influence
on lesion development (8, 9). In addition, the choice of
the endpoint parameters and relative methods in the
evaluation of atherosclerosis has been quite variable.
The choice of the experimental model is also relevant in
explaining the different outcome: in some cases athero-
genesis has been induced by drastic dietary changes,
quite different from the pathophysiological conditions
occurring in humans. Ideally, animal models showing
similarities with the inception and progression of human
atherosclerosis should be used, and control oil should
be carefully chosen (7). The majority of experimental
studies available in the literature do not meet these cri-
teria.
Studies in non-human primates 
Monkeys have been used to determine the effects of
n-3 fatty acids on lipoprotein cholesterol and triglyc-
eride plasma levels (10-13), and on atherosclerosis de-
velopment (14-16). Almost all these studies are difficult
to compare with one another due to metabolic differ-
ences between species and to different study designs.
Usually, n-3 fatty acids were substituted for fat in high
amounts, so that the experimental results can be either
attributed to n-3 fatty acid or to the removal of hyper-
lipidemic (saturated) fatty acids. A consistent finding in
monkey studies has been the reduction in plasma HDL-
cholesterol, an effect often observed in other species
(7). The development of atherosclerosis in general ap-
pears to be retarded or diminished (14, 15). These re-
sults were obtained with the concomitant removal of
saturated fats from the diet, replaced by high amounts
of fish oil without balancing the saturated/unsaturated
ratio. Studies aimed at demonstrating the effect of al-
pha-linolenic acid (ALA) on atherogenesis also support
a protective effect for this specific n-3 fatty acid (17,
18). In one regression study, dietary supplementation
with a relatively low dose of fish oil (2.5% of total ener-
gy intake) in addition to an atherogenic and to a thera-
peutic diet, using sunflower oil as control for both,
caused an increase in cholesterol and phospholipid
content in the aortic intima and no changes in athero-
sclerosis (16). In an in vivo baboon model, high doses of
fish oil - against olive oil supplementation - prevented
platelet deposition on a plastic vascular shunt and vas-
cular lesion formation in response to mechanical vascu-
lar injury in endarterectomized carotids as well as in un-
injured aortas (19). Recently, in a macaque model, the
effect of fish oil on the long-term occlusive tendency of
aortocoronary vein bypass grafts was evaluated and
found ineffective against olive oil (20).
Studies in swine
Pigs have been widely used in studies of lipoprotein
metabolism, which appears to be similar to humans,
and for the study of effects on atherosclerosis, since
spontaneous atherogenesis occurs in this species with
an early spontaneous beginning. However, native lesion
development in the pig is slow, and needs to be accel-
erated by a high-fat diet, cholesterol and bile acids sup-
plementation. Fish oils have usually decreased tri-
glycerides and HDL-cholesterol (7). The effects on ath-
erosclerosis are, again, conflicting. A significant dose-
dependent reduction in the extent of aortic and coro-
nary luminal encroachment has been sometimes ob-
served when the vessel was mechanically abraded,
while atherosclerosis progression was prevented in
non-abraded arteries (21-24). However, aortic lesion
area was not reduced in one set of studies (21-24). In
addition, the question of lesion regression was specifi-
cally addressed. A favorable effect of fish oil supple-
mentation after a period of atherosclerosis induction by
an atherogenic diet was observed in one set of experi-De Caterina and Zampolli
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ments, and regression appeared to be more evident
with low  plasma cholesterol levels. In these studies,
however, there was no control oil or a control oil with a
P/S fatty acid ratio different from that of fish oil (25, 26).
When a control oil with a matching P/S fatty acid ratio
was used in one lesion-regression study, fish oil had no
effect on lesion regression (27). This was accompanied
by an unfavorable increase in low-density lipoproteins
(LDL), decrease in HDL, and increased susceptibility of
LDL to oxidation (28). 
Studies in rabbits
Rabbits provide a convenient model for atherosclero-
sis, since atherosclerosis can be easily and quickly in-
duced in this species. This is usually achieved by feed-
ing either a cholesterol-rich or a casein-based, fat-free
diet. In addition, Watanabe heritable hyperlipidemic
rabbits (WHHL), lacking functional native LDL receptors
and thereby promoting atherosclerosis, are a well-es-
tablished atherosclerosis model, resembling one type of
human inheritable type of atherosclerosis. However,
lipoprotein metabolism is different in rabbits and hu-
mans. In rabbits, an increase in dietary cholesterol does
not result in LDL, but on β-very-low density lipoproteins
(β-VLDL) elevation, so that any change in lipoprotein
levels is not necessarily pertinent to most situations oc-
curring in humans. Studies aimed at verifying the effect
of n-3 fatty acids in rabbit atherosclerosis models are
inconsistent both with regard to lipoproteins and
triglyceride/cholesterol concentrations (7). Moreover,
results of n-3 fatty acid supplementation on atheroscle-
rosis are conflicting in this species, and most studies
lack an adequate control. Fish oils were reported to in-
hibit atherosclerosis development in cholesterol fed
rabbits (29-31), to enhance lesion formation (32, 33), or
to have no effect (34, 35). However, fish oils reduced in-
timal proliferation in arteries after ballon injury (36, 37).
This effect was inversely related to serum cholesterol
values, in agreement with data obtained in porcine
models (26, 38). The efficacy of fish oil was also appar-
ently enhanced by vitamin E supplementation (31).
In WHHL rabbits, n-3 fatty acids were initially report-
ed to have either no effect on plasma lipids and aortic
lesion size (39), or to lower triglycerides, total lipopro-
teins and cholesterol in female rabbits, but to be inef-
fective on lesion size of treated vs. untreated controls
(40). With a similar experimental protocol, but with dif-
ferent criteria for lesion evaluation, fish oil reduced
triglyceride and cholesterol levels and aortic lesions
(41). Recently, a direct comparison of fish oil against
olive oil treatment confirmed the occurrence of a hy-
polipidemic effect of fish oil in this species, and these
findings were associated with a retardation of athero-
sclerosis development in young WHHL rabbits (42).
Studies in mouse models
Studies in mouse models have been scarce. Reiner et
al evaluated the effect of n-3 fatty acids on the develop-
ment of atherosclerosis and on the secretory activity of
peritoneal macrophages in the atherosclerosis-suscep-
tible strain C57BL/6J (43). The authors compared a sat-
urated fatty acid- and a fish oil-supplemented diet; fish
oils diminished the lesion size. Macrophages displayed
a decreased ability to produce basal tumor necrosis
factor (TNF)-α and lipopolysaccharide (LPS)-elicited
TNF-α and interleukin (IL)-1β production, a reduction of
lipoprotein lipase expression, and an enhancement of
nitrate synthesis, used as a nitric oxide production in-
dex. In a recent study on murine macrophages, fish oil
reduced the expression of intercellular adhesion mole-
cule (ICAM)-1 and of scavenger receptor A type I and II
(44). These findings suggest an effect of n-3 fatty acids
on macrophage phenotypes and on their role in lesion
formation.
Recently, transgenic mouse models of atherosclero-
sis have been introduced (45). The LDL receptor-defi-
cient (LDLR-/-) mouse develops atherosclerosis when
put on a Western-type, high-fat diet (46). In this model,
LDL is not efficiently cleared from plasma, and hyper-
cholesterolemia and atherogenesis proceed with a pat-
tern similar to the human situation.
The apolipoprotein (apo) E-deficient mouse is anoth-
er atherogenesis model (47, 48). In this model, there is
no need to modify the diet, since atherosclerosis pro-
ceeds spontaneously and very rapidly. The serum lipid
profile is quite different from the human condition, how-
ever, since apo E is a constituent of all lipoproteins ex-
cept LDL, and serves as a ligand for receptors involved
in the clearance of chilomicrons and VLDL remnants.
The only human counterpart of this situation is the ge-
netic defect of apo E, a rare clinical condition that leads
to severe atherosclerosis.N-3 Fatty Acids: antiatherosclerotic effects - evidence and mechanisms
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In both LDL-receptor knockout and apo E knockout
models, atherosclerotic lesions begin to spread from
the thoracic aorta to the whole aorta and its main
branches, predominantly at bifurcation sites. The lesion
formation pattern is similar in both models (49). Al-
though gender influence is controversial, actively pro-
duced estrogens seem protective.
While the effect of n-3 fatty acids in the LDL receptor
model had not been the object of any published work
until recently, studies of n-3 fatty acids in apo E-/- mice
have been done. Calleja et al fed apo E-/- mice diets en-
riched with different oils commonly used in human nu-
trition, without adding cholesterol (50). Following evalu-
ation of the lesion area, male animals appeared to re-
spond to sunflower oil, rich in n-6 polyunsaturated fatty
acids, while females responded to palm oil and elevated
concentrations of olive oil, rich in monounsaturated fat-
ty acids. Adan et al recently fed 7-week-old apo E-defi-
cient mice an atherogenic diet in the presence or ab-
sence of DHA supplementation (1% final concentration)
for 8 weeks (51), and observed no effect of DHA on ath-
erosclerosis: the size and extension of lesions in the
aortic arch and the thoracic and abdominal aorta were
similar in both experimental groups. Cholesterol and
cholate in the diet might have influenced these results.
We recently evaluated the effects of n-3 (in the form of
fish oil) compared with n-6 fatty acids (in the form of
corn oil) in both the apo E- and the LDL receptor-
knockout models. Both n-3 and n-6 fatty acid supple-
mentation retarded atherosclerosis development in
LDL receptor-/- mice, with a stronger effect seen with
n-3 fatty acids, especially in the regions (such as the
aortic arch) more susceptible to lesion development.
There was an important strain-dependence of the ef-
fect, with no protection against atherosclerosis in apo
E-/- mice (52).
In summary, animal experimental studies with n-3 fat-
ty acids are hampered by differences in study design
and species. No definite claim on the existence of true
antiatherogenic effects of n-3 fatty acids can be done to
date on this basis.
Studies in humans
Nutritional intake of n-3 fatty acids is highly likely to
lead to cardioprotection. This has been recently con-
firmed by a 30-yr follow-up in men who were free of
overt cardiovascular disease at baseline and who con-
sumed up to 35 g fish per day (53); and recently, base-
line blood values of long-chain n-3 fatty acids have
been associated with the reduced risk of sudden death
in a nested-case study conducted on healthy subjects
from the Physicians’ Health Study cohort (54). Recently,
the American Heart Association recommended that all
adults eat fish twice a week as a means of coronary
heart disease prevention (55). However, because of the
multifactorial nature of ischemic heart disease, of which
atherosclerosis is one, albeit important, component, ev-
idence about the occurrence of a true antiatherogenic
effect of n-3 fatty acids in humans is not easy to gather.
Autopsy studies in Alaskan natives (consuming high
amounts of fish-derived products) and non-natives,
mostly consuming Western-type diets provide circum-
stantial evidence about a lesser extent of atherosclero-
sis in populations exposed to a high nutritional intake of
n-3 fatty acids. Newman et al (57) reported reduced per-
cent of intima covering with fatty streaks and raised le-
sion in Alaskan natives, with a high n-3 fatty acid dietary
intake (56), vs. non-natives (57). In their study, the mag-
nitude of difference in fatty streak development appears
larger in younger age groups (57) (Fig. 1), suggesting an
effect of diet mainly in the early events leading to fully
developed atherosclerotic lesions. Prospective studies
in humans are few, but mostly pointing to the true oc-
currence of such effects. A study of high-dose n-3 fatty
acid supplementation on coronary artery disease re-
gression, evaluated by angiography, was negative (58),
but a subsequent well-controlled study (the study on
prevention of coronary atherosclerosis by intervention
with marine omega-3 fatty acids (SCIMO)) showed a
slower progression in subjects supplemented with low-
er doses (1.65 g/day of EPA + DHA) (59). Interestingly,
the same authors recently reported no effect of the
treatment on carotid intima-media thickness evaluated
by carotid ultrasound in the very same subjects (60), in-
dicating some district-specificity for the fish oil effect. It
has been speculated that 0.5-2.0 g n-3 fatty acids per
day are effective in reducing clinical endpoints (61). By
contrast, higher doses would yield no effect (58). How-
ever, this contention is based on very few studies exam-
ining the effects of these substances on true atheroge-
nesis and not on a mixed endpoint. One study after
coronary bypass surgery indicated that n-3 fatty acids
significantly reduced vein graft stenosis (62), a processDe Caterina and Zampolli
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which may be regarded as an accelerated form of ather-
osclerosis. Studies on restenosis after percutaneous
coronary angioplasty have been contradictory and, in
the end, largely inconclusive (63-74), although issues of
study design still leave open the possibility that n-3 fat-
ty acids can have some efficacy on restenosis (75).
Restenosis after percutaneous interventions is, howev-
er, the result of a mechanical injury to an already dis-
eased vessel wall, and its relevance to native athero-
sclerosis is controversial.
Very recently, the results of a large Japanese study
(the Japan EPA Lipid Intervention Study, JELIS) in over
20,000 Japanese subjects (overall with a high baseline
intake of n-3 fatty acids compared to Western popula-
tions) were presented. Subjects were treated with either
a relatively high dose of EPA (1800 mg/day) or nothing,
against the background of optimal medical therapy. The
study examined whether EPA administration, in both a
primary and a secondary prevention setting, could re-
duce major coronary events, including sudden cardiac
death, fatal and non-fatal myocardial infarction, unsta-
ble angina, the number of cases of angioplasty/stenting
or coronary bypass grafting, in a prospective, double-
blind open-label study with blinded adjudications of
endpoints (76). In an average follow-up of 4.6 yrs, the
study found a significant (19%, p=0.01) reduction in the
combined primary endpoint, which was due to a reduc-
tion in myocardial infarction and unstable angina but
not, at variance from previous studies, in sudden car-
diac death. This reduction appeared to be totally inde-
pendent from any change in serum cholesterol (77).
These results are important indirect evidence in humans
for a reduction in either the progression of atherosclero-
sis or its propensity to acute complications, such as
plaque rupture and coronary thrombosis.
In summary, based on at least one placebo-controlled
prospective study of native atherosclerosis in the coronary
arteries, a placebo-controlled prospective study in coro-
nary bypass surgery grafts, and a recent large-scale study
on coronary events, human studies provide stronger evi-
dence of an antiatherogenic effect of n-3 fatty acids than
do animal studies. 
PUTATIVE MECHANISMS BY WHICH N-3 FATTY ACIDS
INTERFERE WITH ATHEROGENESIS
Molecular mechanisms in atherogenesis
The initial event in atherosclerosis development is a
condition of endothelial dysfunction, that precedes any
morphologic evidence of endothelial damage (78). A
number of different stimuli (toxins, shear stress, ciga-
rette smoking and high cholesterol levels) can trigger
Fig. 1 - Percent of coverage of the 
aorta with fatty streaks (open areas)
and raised plaques (grey areas) in
Alaskan natives vs. non-natives, divid-
ed by age. Notice the larger differ-
ence, attributable to the prevalence of
fatty streaks, in younger age groups.
Redrawn, modified, from (57).N-3 Fatty Acids: antiatherosclerotic effects - evidence and mechanisms
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endothelial dysfunction. One type of endothelial dys-
function is termed endothelial activation. In this, the en-
dothelium modifies its phenotype in a pro-adhesive di-
rection, triggering an increased adhesion of circulating
monocytes. Their subsequent infiltration in the arterial
intima is one of the first visible findings in atherosclero-
sis. In the intima, monocytes become activated, and be-
gin to incorporate circulating LDL that have become ox-
idized through the exposure to reactive oxygen species
of both endothelial and macrophagic origin; therefore,
initiating the formation of the fatty streak (79) (Fig. 2). 
Atherosclerosis and inflammation share similar basic
mechanisms, involving the adhesion of leukocytes to
the vascular endothelium in their early phases. Multiple
protein families, each with a distinct function, provide
“traffic signals” for leukocytes. These include: 
a) the “selectin” family of adhesion molecules; 
b)  chemoattractants, some of which (“classical”
chemoattractants), such as N-formyl peptides, com-
plement components, leukotriene B4 and platelet-
activating factor, act broadly, on neutrophils,
eosinophils, basophils and monocytes, while more
recently described “chemokines”, such as monocyte
chemoattractant protein-1 (MCP-1) and IL-8, have
selectivity for leukocyte subsets; 
c) the immunoglobulin (Ig) superfamily members on the
endothelium (intercellular adhesion molecule (ICAM)-
1, ICAM-2, ICAM-3, and vascular cell adhesion mole-
cule (VCAM)-1), recognizing “integrin” ligands on the
leukocyte surface.
For neutrophil and, probably, lymphocyte adhesion,
selectins mediate initial tethering of the circulating
leukocyte over the endothelium, allowing it to roll over
the endothelium, considerably slowing down its speed,
and allowing leukocytes to “sense” the presence of
chemotactic gradients. Final firm attachment of leuko-
cytes to the endothelium requires the interaction of inte-
grin ligands on the leukocyte surface with Ig superfami-
ly members, expressed on the endothelium, such as
ICAM-1, ICAM-2 and VCAM-1. The multiple molecular
choices available for each of these ligand-ligand inter-
actions provide great combinatorial diversity in signals,
allowing the selective responses of different leukocyte
classes to inflammatory agents, the preferential recircu-
lation patterns of lymphocyte subpopulations, or the
selective binding of monocytes to the arterial endotheli-
um during early phases of atherogenesis.
Monocyte recruitment into the intima of large arteries
is specific for atherosclerosis as compared to other
forms of leukocyte-endothelial interactions. Therefore,
it was suggested that these localized monocyte-
endothelium interactions reflect specific molecular
Fig. 2 - A scheme of the modifica-
tions of the arterial intima occurring
in early atherogenesis. De Caterina and Zampolli
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changes in the adhesive properties of the endothelial
surface, leading to the surface expression of “athero-
ELAMs”, ie endothelium-leukocyte adhesion molecules
(ELAMs) expressed in the early phases of atherosclero-
sis. The first such protein, originally identified in the rab-
bit hypercholesterolemic model, is VCAM-1, a member
of the Ig superfamily, expressed on human vascular en-
dothelium at least in two molecular forms. Both forms
are able to bind a heterodimeric integrin receptor, VLA4,
whose leukocyte selectivity of expression, on mono-
cytes and lymphocytes, but not on neutrophils, can ex-
plain the selectivity of monocyte recruitment in early
atherogenesis (80). Endothelial cells express VCAM-1
early during cholesterol feeding in the rabbit, before
the appearance of macrophages/foam cells in the inti-
ma of developing fatty streak, in a temporal pattern
consistent with its pathogenetic role in lesion devel-
opment. Pathophysiologically relevant stimuli for
VCAM-1 expression in atherogenesis could include
minimally oxidized LDL or β-VLDL, the advanced gly-
cosylation end-products (AGEs) associated with dia-
betes, lipoprotein (Lp)(a), or perhaps homocysteine,
elevated in homocysteinuria and in subtler forms of
congenital or acquired enzyme defects in its biosyn-
thetic pathway. In addition to these humoral stimuli,
VCAM-1 endothelial gene expression also responds
to hemodynamic forces, thus potentially explaining
the localization of atherosclerosis in particular points
of the arterial vasculature. For a general review on
these issues, see De Caterina et al (80). 
The progression from fatty streak to atheroma is dri-
ven by the production of cytokines and chemo-attrac-
tants that determine the intimal accumulation of leuko-
cytes, smooth muscle cells and fibroblasts, as well as
platelet adhesion. The thin-capped, lipid-rich athero-
matous plaques have a strong tendency to rupture and
are at risk of complicating with thrombosis, which is
usually the ultimate event leading to unstable angina
and myocardial infarction (81).
Therefore, there are multiple potential points of ac-
tion of n-3 fatty acids on atherogenesis. The best-char-
acterized ones are briefly reviewed below.
Effects of n-3 fatty acids on plasma lipids
In humans, n-3 fatty acids decrease serum triglyc-
erides, an effect that is pronounced in marked hyper-
triglyceridemia. VLDL-cholesterol is reduced, while
LDL-cholesterol tends to be either elevated or un-
changed (82, 83). In patients with mixed hyperlipidemia
and in marked hypertriglyceridemia, n-3 fatty acids are
a highly effective means of reducing both triglyceride
and VLDL. Therefore, n-3 fatty acids appear to reduce
one of the atherogenic triggers.
Effects of n-3 fatty acids on cellular responses
to atherogenic triggers
Dietary intake of n-3 fatty acids, such as EPA and
DHA, allows their incorporation in the phospholipids of
cell membranes replacing arachidonic acid (AA). Origi-
nally, the beneficial effects of n-3 fatty acids on the car-
diovascular system were attributed to their substitution
of AA. Metabolites that derive from n-3 fatty acid enzy-
matic metabolization (through cyclooxygenase, lipoxy-
genase and cytochrome P-450 monoxygenase) are less
pro-thrombotic and vasoconstrictive compared to the
corresponding AA derivatives. Many vascular effects of
n-3 fatty acids are equally shared by DHA and EPA, or
possibly even more prominently shown by DHA than
EPA. Since DHA, at variance from EPA, is a poor sub-
strate for metabolization into eicosanoids, effects of n-
3 fatty acids other than eicosanoid generation are likely
to play a greater role in preventing atherogenesis. 
In recent years, the direct effects on endothelial acti-
vation have been demonstrated. These include:
• the reduced production of cytokines such as IL-1 and
TNF in LPS-stimulated monocytes (84); 
• the reduced production of the mitogen and smooth
muscle cell attractant platelet-derived growth factor
(PDGF -A and -B) protein and m-RNA (85, 86); 
• the reduced expression of tissue factor by monocytes
(87);
• an increase of endothelial nitric oxide bioavalability
(88);
• the specific downregulation of gene expression for
MCP-1 (89); and 
• the reduced expression of endothelial adhesion mole-
cules, essential for monocyte adhesion to sites of in-
flammation and dysfunctional endothelium (90).
Research on this last aspect will be now highlighted
in greater detail, since it provides a potentially compre-
hensive explanation of the behavior of these agents as
modulators of gene expression.N-3 Fatty Acids: antiatherosclerotic effects - evidence and mechanisms
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Modulation of endothelial-leukocyte interac-
tions by n-3 fatty acids
We used human adult saphenous vein endothelial
cells activated by cytokines, in an in vitro model of these
early steps in atherogenesis, first, assessing the effects
of various fatty acids on the surface expression of en-
dothelial leukocyte adhesion molecules, and, subse-
quently, characterizing mechanisms and functional rele-
vance of these effects. One n-3 fatty acid, DHA, when
added to cultured endothelial cells, hours to days be-
fore the stimulation with cytokines, early enough to al-
low a significant incorporation of this fatty acid in cell
membrane phospholipids, significantly inhibited events
connected with endothelial activation. These included
the expression of adhesion molecules such as VCAM-1,
E-selectin and, to a lesser extent, ICAM-1 after stimula-
tion with virtually any stimulus able to elicit the coordi-
nated expression of such genes (90, 91). Therefore, this
inhibition could be demonstrated with IL-1α and IL-1β,
TNF-α, IL-4 and LPS (Fig. 3). Inhibition of adhesion mol-
ecule expression occurred in a range of DHA concentra-
tions compatible with nutritional supplementation of
this fatty acid to normal Western diets. In addition, this
inhibition occurred at any time point after the appear-
ance of the cytokine effect, modifying the specific kinet-
ics of the surface expression of adhesion molecules,
and was strictly related in its magnitude to the extent of
incorporation into total cell lipids. The extent of VCAM-
1 inhibitory effect paralleled the incorporation of DHA
and the overall increase in incorporation of n-3 fatty
acids and was inversely related to the content of n-6 fat-
ty acids. Following the fate of 14C-labelled DHA into
cell phospholipids, we could show a significant incor-
poration of DHA into the phosphatidyl ethanolamine
pool. This is a specific and not the most abundant phos-
pholipid pool, likely in the inner plasma membrane; and
therefore, possibly in a strategic position to alter intra-
cellular signal transduction pathways. This effect was
not limited to the expression of transmembrane mole-
cules involved in leukocyte recruitment. It also ap-
peared to occur for other cytokine-activated products,
such as the soluble proteins IL-6 and IL-8, involved in
either the amplification of the inflammatory response
(IL-6), or in the specific chemoattraction for granulo-
cytes (IL-8). The effect was also accompanied by a
functional counterpart, i.e. a reduced monocyte or
monocytoid cell adhesion to cytokine activated en-
dothelium. Compared to DHA, EPA was a weaker in-
hibitor of the expression of these molecules and of
monocyte adhesion, although still more potent than
other fatty acids. We also showed that DHA effects on
VCAM-1 expression are accompanied by parallel reduc-
tions in VCAM-1 mRNA steady state levels, as assessed
by Northern blot analysis (90, 91). Similar results, in ex-
periments with remarkably similar design, were later re-
ported by Weber et al (92). The authors also carried
these investigations one step further, demonstrating an
inhibition by DHA of the activation of the NF-κB system
of transcription factors (92), which controls the coordi-
Fig. 3 - The inhibition of
adhesion molecule ex-
pression by DHA, oc-
curring with diverse
stimuli, including IL-1α
and IL-1β, TNF-α, IL-4
and LPS. Asterisks de-
note significant differ-
ences at p<0.01. From
De Caterina, et al, un-
published.De Caterina and Zampolli
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nated expression of adhesion molecules and of leuko-
cyte-specific chemoattractants upon cytokine stimula-
tion (93, 94).
We further analyzed endothelial effects of various fat-
ty acids differing in chain length, number, position (n-3
vs. n-6 vs. n-9) and cis/trans configuration of the double
bonds. Using VCAM-1 surface expression as a readout,
we concluded that: 
a) saturated fatty acids are inactive; 
b) potency of polyunsaturated fatty acids increases with
the number of unsaturations;
c) potency does not depend on chain length;
d) the single double bond present in the monounsatu-
rated fatty acid oleic acid is indeed sufficient to pro-
duce all the effects obtainable with higher unsaturat-
ed fatty acids, albeit at higher concentrations;
e) for such an effect to occur, even the configuration (cis
vs. trans) of the double bond does not really matter,
since oleic acid (19:1 n-9 cis) and its trans stereoiso-
mer elaidic acid are of equal potency (95). In addition,
inhibition of NF-κB activation could be reproduced
upon incubation of endothelial cells with oleic acid
(96).
Possible molecular mechanisms by which 
unsaturated fatty acids inhibit endothelial 
activation
In order to ascertain mechanisms for these effects we
demonstrated the inhibition of NF-κB activation by DHA
(the most potent fatty acid inhibitor of endothelial acti-
vation) in parallel with measurements of  hydrogen per-
oxide production by cultured endothelial cells. This re-
active oxygen species (or one of more of its down-
stream unstable products) appears to be a critical medi-
ator of NF-κB activation (Fig. 4). We had previously
shown that treatment of endothelial cells with polyethyl-
ene glycol (PEG)-complexed superoxide dismutase (a
cell membrane-permeable form of this enzyme, which
catalyzes the conversion of superoxide anion to hydro-
gen peroxide) does not much affect VCAM-1 m-RNA
production. On the contrary, a treatment with PEG-cata-
lase, which acts by accelerating the degradation of hy-
drogen peroxide, quenches endothelial activation (80).
This suggested that hydrogen peroxide (or some of its
downstream products) is more relevant than upstream
products (i.e. superoxide anion) in the activation of NF-
κB. We also assessed the production of intracellular hy-
drogen peroxide (and/or its downstream products) by
dichloro-fluoresceine before or after stimulation with IL-
1 or TNF. In both these experimental systems, we could
document a reduction in baseline production of reactive
oxygen species after cell membrane enrichment with
DHA, and an even more pronounced dampening of the
increase produced by stimulation with cytokines. Satu-
rated fatty acids served as a negative control in these
experiments. Therefore, our current understanding of
these phenomena is that a property related to fatty acid
peroxidability (the presence of multiple double bonds),
usually regarded as a detrimental consequence of
polyunsaturated fatty acid enrichment of cell mem-
branes, is directly related to this putatively favorable
outcome (Fig. 5).
These results have spurred the reappraisal of how the
action of fatty acids on endothelial cells could modu-
late, not only general phenomena such as atherogene-
Fig. 4 - A scheme of the intracellular signal transduction pathways
leading to increased gene expression of target genes upon en-
dothelial cell exposure to atherogenic triggers. Redrawn, modified,
from (93).N-3 Fatty Acids: antiatherosclerotic effects - evidence and mechanisms
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sis but also, potentially, inflammation or some immune
responses. Since all these effects occurred even in the
presence of inhibitors of metabolic conversion of fatty
acids to eicosanoids, they provide a novel explanation
for the modulating effect of n-3 fatty acids in atheroge-
nesis, distinct from the now outdated hypothesis of
substrate substitution (97). The results with oleic acid
also might partially explain the beneficial effects of
olive-oil rich (“Mediterranean”) diets on atherogenesis.
Notably, incorporation of oleic acid likely occurred at
the expense of saturated fatty acids; therefore, disclos-
ing the potentially additive effects of n-3 fatty acids,
which mostly substitute less unsaturated fatty acids in
the membrane phospholipid pools. If extended to cell
types different from endothelial cells such as the mono-
cyte-macrophage that also undergo the “activation”
phenomena when stimulated by cytokines or LPS, such
effects could provide a coherent explanation for several
previous observations such as the inhibition of cytokine
formation by LPS-activated macrophages (84). These
effects might be associated closely with the peroxid-
ability of polyunsaturated fatty acid.
Future research will further elucidate molecular as-
pects of these phenomena (90) and expand the greater
scope of this research line to explain the many biologi-
cal effects of unsaturated fatty acids as modulators of
biological responses to cytokines.
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